CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Avoid common budget mistakes by knowing what not to include in a budget. This quick intro highlights pitfalls and simple tweaks to improve your spending plan.
26,809 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A high-profile estate story can illuminate practical steps you can take to protect loved ones and support causes you ...
Kazakhstan's central bank is considering a $350 million crypto-related portfolio funded in part by gold reserves. Off...
Divisadero Street Capital Management upped its stake in Dave (DAVE), fueling questions about a potential buying oppor...
A recent insider move at Precigen has many investors asking if a CFO’s share sale signals trouble. This deep-dive bre...
Novartis faces a nuanced path in 2026, balancing new therapies with cost discipline. This guide breaks down the key d...
Plug Power stock surging momentum is turning heads after a February stumble. This article breaks down the catalysts, ...
A new era is arriving for fan-created music. Spotify and Universal Music Group are piloting an AI-powered remix platf...
This in-depth piece dives into Chile's bold tax reform plan and what it could mean for growth, investment, and global...
A leading LNG stock jumped 32% this stock year, investor took profits, and a massive exit followed. Here’s how to und...
A mid-sized fund wrapped up a $9 million exit from a major pawn shop operator after a rally of about 150% over the ye...
If SpaceX goes public with enough float, it may land in Vanguard-friendly CRSP-based ETFs. This guide breaks down wha...